AUTHORS
Oliver A Cornely, Tadeusz Robak, MD2, Antoine Azar3, Paolo Ghia, MD, PhD4, Nicole Lamanna, MD5, Lydia Scarfò, MD6, Martin Simkovic, MD7, Livio Trentin, MD8, Heidemarie Buchinger9, Evgenii Chizhikov10, Katja Pachner11, Susan O'Brien, MD12
AFFILIATIONS
1 University of Cologne, Cologne, Germany
2 Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
3 Johns Hopkins University, Baltimore, United States
4 IRCCS Ospedale San Raffaele, Milano, Italy, Università Vita-Salute San Raffaele, Milano, Italy
5 Columbia University, New York, New York, United States
6 IRCCS Ospedale San Raffaele, Milano, Italy, Università Vita-Salute San Raffaele, Milano, Italy
7 Faculty of Medicine in Hradec Králové, University Hospital and Charles University, Hradec Kralove, Czech Republic
8 University of Padova, Padova, Italy
9 Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
10 Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
11 Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
12 UCI Health Chao Family Comprehensive Cancer Center, Irvine, United States
ABSTRACT
Introduction:
Up to 85% patients with chronic lymphocytic leukemia (CLL) develop hypogammaglobulinemia during the course of the disease, resulting from both the underlying malignancy and CLL-directed therapies (i.e., secondary immunodeficiency [SID]). This contributes to the characteristic increased risk of serious infections, which represent a major cause of morbidity and mortality observed in this patient population. Intravenous immunoglobulin (IVIG) is recommended for prophylaxis for severe or recurrent infections (i.e., secondary infection prophylaxis) in selected CLL patients with SID; however, the efficacy of IVIG as primary prophylaxis against initial infection has not yet been established.
Pro-SID is the first large randomized, placebo-controlled Phase 3 trial in the era of modern CLL therapy to evaluate the efficacy and safety of IVIG as primary infection prophylaxis in patients with CLL and hypogammaglobulinemia.
Methods:
Pro-SID (NCT04502030) was a double-blind, prospective, multicenter study including patients ≥18 years of age who were treatment-naïve or with relapsed/refractory CLL, had hypogammaglobulinemia (immunoglobulin G [IgG] level <500 mg/dL), and were undergoing antineoplastic treatment. Diagnosis of CLL was established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. Key exclusion criteria were receipt of IgG treatment within 3 months prior to screening, antibiotic prophylaxis and/or treatment within 7 days prior to baseline, and current major infection or >1 major infection in the previous 6 months before baseline.
Eligible patients were randomized 1:1 to receive an infusion of 10% human normal IVIG (Panzyga®, Octapharma; 0.4 g/kg) or placebo (0.9% w/v sodium chloride) every 4 weeks for up to 13 infusions over 52 weeks, in addition to standard-of-care infection prophylaxis according to local institutional practice. The primary endpoint was the occurrence of ≥1 major infection, as assessed by an independent endpoint adjudication board. Secondary endpoints included overall infection rate and the frequency and duration of anti-infective prophylaxis (antibacterials and antivirals). Safety endpoints included adverse events.
Results:
A total of 247 patients received IVIG (N=124) or placebo (N=123) in the study. Baseline characteristics were comparable between groups. The mean (standard deviation [±SD]) age was 67 (±9.1) years; most patients were male (62.3%) and had relapsed/refractory CLL (70.9%). Small molecule inhibitors were the most frequently used antineoplastic therapy in both groups (IVIG 62.9%, placebo, 65.9%). Mean (±SD) IgG level at baseline was 327 (±108) mg/dL.
The primary endpoint was met: there was a statistically significant reduction in the incidence of major infections in the IVIG group versus the placebo group. The proportion of patients with ≥1 adjudicated major infection was 11.3% (n=14) versus 22.0% (n=27), representing a 48.6% relative risk reduction. This resulted in a p-value of 0.0108 for the primary endpoint analysis after including imputed data for patients with missing values. The secondary endpoint of overall infection rate was lower with IVIG than placebo (1.2 vs. 1.7 infections per patient-year), although that difference did not meet the prespecified significance threshold at the 2.5% significance level (p=0.0463). The frequency and duration of anti-infective prophylaxis treatments were similar between groups, with a mean of 1.9 medications administered over a median duration of 363 days in both groups.
The safety and tolerability profile of the IVIG was consistent with previously reported safety outcomes. The proportion of patients with treatment-emergent adverse events (TEAEs) was comparable between groups (IVIG, 84.7%; placebo, 80.5%). One serious adverse event was assessed as related to IVIG, which was a thromboembolic event.
Conclusions:
Pro-SID is the first large, randomized study to evaluate the use of IVIG as primary infection prophylaxis in patients with CLL and hypogammaglobulinemia who are receiving antineoplastic therapy, including small molecule inhibitors. In these patients, IVIG significantly reduced major infections by 48.6% compared with placebo, despite both groups receiving standard of care infection prophylaxis. Together with a safety profile consistent with previous experience, these results support the use of IVIG as primary infection prophylaxis.
DISCLOSURES
Oliver A Cornely: MSD, Shionogi, - Honoraria; MSD, Shionogi, - Consultancy (Includes expert testimony)